Skip to contentA
aTYR PHARMA INC
A
ATYRaTYR PHARMA INC Q3 2024 · 10-Q
Revenue$0.00$0.00−100.0% vs Q3 2023 Net Income-$17.26M-$17.26MN/M vs Q3 2023 EPS Diluted-$0.23-$0.23N/M vs Q3 2023 Operating Income-$18,143,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
aTYR PHARMA INC · CIK 1339970 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$13,173,000N/M ended Sep 30, 2024 · filed Nov 7, 2024 · 38 d after period end